|
1
|
Rodriguez-Galindo C, Orbach DB and
VanderVeen D: Retinoblastoma. Pediatr Clin North Am. 62:201–223.
2015. View Article : Google Scholar
|
|
2
|
McEvoy JD and Dyer MA: Genetic and
epigenetic discoveries in human retinoblastoma. Crit Rev Oncog.
20:217–225. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rangamani S, SathishKumar K, Manoharan N,
Julka PK, Rath GK, Shanta V, Swaminathan R, Rama R, Datta K, Mandal
S, et al: Paediatric retinoblastoma in India: Evidence from the
National Cancer Registry Programme. Asian Pac J Cancer Prev.
16:4193–4198. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Truong B, Green AL, Friedrich P, Ribeiro
KB and Rodriguez-Galindo C: Ethnic, racial, and socioeconomic
disparities in retinoblastoma. JAMA Pediatr. 169:1096–1104. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wyse E, Handa JT, Friedman AD and Pearl
MS: A review of the literature for intra-arterial chemotherapy used
to treat retinoblas-toma. Pediatr Radiol. 46:1223–1233. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Theodoropoulou S, Brodowska K, Kayama M,
Morizane Y, Miller JW, Gragoudas ES and Vavvas DG: Aminoimidazole
carboxamide ribonucleotide (AICAR) inhibits the growth of
retinoblastoma in vivo by decreasing angiogenesis and inducing
apoptosis. PLoS One. 8:e528522013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Han G, Lu K, Huang J, Ye J, Dai S, Ye Y
and Zhang L: Effect of Annexin A1 gene on the proliferation and
invasion of esophageal squamous cell carcinoma cells and its
regulatory mechanisms. Int J Mol Med. 39:357–363. 2017. View Article : Google Scholar :
|
|
8
|
Martinez E and Trevino V: Modelling gene
expression profiles related to prostate tumor progression using
binary states. Theor Biol Med Model. 10:372013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stella F, Pedrazzini E, Baialardo E, Fantl
DB, Schutz N and Slavutsky I: Quantitative analysis of CKS1B mRNA
expression and copy number gain in patients with plasma cell
disorders. Blood Cells Mol Dis. 53:110–117. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu L, Fan S, Zhao J, Zhou P, Chu S, Luo J,
Wen Q, Chen L, Wen S, Wang L and Shi L: Increased expression of
Cks1 protein is associated with lymph node metastasis and poor
prognosis in nasopharyngeal carcinoma. Diagn Pathol. 12:22017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi L, Wang S, Zangari M, Xu H, Cao TM, Xu
C, Wu Y, Xiao F, Liu Y, Yang Y, et al: Over-expression of CKS1B
activates both MEK/ERK and JAK/STAT3 signaling pathways and
promotes myeloma cell drug-resistance. Oncotarget. 1:22–33.
2010.PubMed/NCBI
|
|
12
|
Zarrabi M, Afzal E, Asghari MH, Mohammad
M, Es HA and Ebrahimi M: Inhibition of MEK/ERK signalling pathway
promotes erythroid differentiation and reduces HSCs engraftment in
ex vivo expanded haematopoietic stem cells. J Cell Mol Med.
22:1464–1474. 2018. View Article : Google Scholar
|
|
13
|
Soares HP, Ming M, Mellon M, Young SH, Han
L, Sinnet-Smith J and Rozengurt E: Dual PI3K/mTOR inhibitors induce
rapid overactivation of the MEK/ERK pathway in human pancreatic
cancer cells through suppression of mTORC2. Mol Cancer Ther.
14:1014–1023. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhan F, Shi L, Wang S, Xu H, Cao TM, Xu C,
Wu Y, Zangari M, Li G and Tricot GJ: CKS1B Mediates
SKP2/p27Kip1-independent myeloma cell survival and disease
progression through activation of MEK/ERK and JAK/STAT3 signaling
pathways. Blood. 114:1262009.
|
|
15
|
Radhakrishnan V, Kumar R, Malhotra A and
Bakhshi S: Role of pet/ct in staging and evaluation of treatment
response after 3 cycles of chemotherapy in locally advanced
retinoblastoma: A prospective study. J Nucl Med. 53:191–198. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ayuk SM, Abrahamse H and Houreld NN: The
role of photobiomodulation on gene expression of cell adhesion
molecules in diabetic wounded fibroblasts in vitro. J Photochem
Photobiol B. 161:368–374. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li L, Dong P, Hou C, Cao F, Sun S, He F,
Song Y, Li S, Bai Y and Zhu D: Hydroxysafflor yellow A (HSYA)
attenuates hypoxic pulmonary arterial remodelling and reverses
right ventricular hypertrophy in rats. J Ethnopharmacol.
186:224–233. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tomar S, Sethi R, Sundar G, Quah TC, Quah
BL and Lai PS: Mutation spectrum of RB1 mutations in retinoblastoma
cases from Singapore with implications for genetic management and
counselling. PLoS One. 12:e01787762017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chawla B, Jain A and Azad R: Conservative
treatment modalities in retinoblastoma. Indian J Ophthalmol.
61:479–485. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Subramanian N, Navaneethakrishnan S,
Biswas J, Kanwar RK, Kanwar JR and Krishnakumar S: RNAi mediated
Tiam1 gene knockdown inhibits invasion of retinoblastoma. PLoS One.
8:e704222013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Martín-Ezquerra G, Salgado R, Toll A, Baró
T, Mojal S, Yébenes M, Garcia-Muret MP, Solé F, Quitllet FA,
Espinet B and Pujol RM: CDC28 protein kinase regulatory subunit 1B
(CKS1B) expression and genetic status analysis in oral squamous
cell carcinoma. Histol Histopathol. 26:71–77. 2011.
|
|
22
|
Shrestha S, Yang CD, Hong HC, Chou CH, Tai
CS, Chiew MY, Chen WL, Weng SL, Chen CC, Chang YA, et al:
Integrated MicroRNA-mRNA analysis reveals miR-204 inhibits cell
proliferation in gastric cancer by targeting CKS1B, CXCL1 and
GPRC5A. Int J Mol Sci. 19:E872017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang CW, Lin CY, Huang HY, Liu HW, Chen
YJ, Shih DF, Chen HY, Juan CC, Ker CG, Huang CY, et al: CKS1B
overex-pression implicates clinical aggressiveness of
hepatocellular carcinomas but not p27(Kip1) protein turnover: An
independent prognosticator with potential p27 (Kip1)-independent
oncogenic attributes? Ann Surg Oncol. 17:907–922. 2010. View Article : Google Scholar
|
|
24
|
Zhan F, Colla S, Wu X, Chen B, Stewart JP,
Kuehl WM, Barlogie B and Shaughnessy JD Jr: CKS1B, overexpressed in
aggressive disease, regulates multiple myeloma growth and survival
through SKP2- and p27Kip1-dependent and -independent mechanisms.
Blood. 109:4995–5001. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zassadowski F, Rochette-Egly C, Chomienne
C and Cassinat B: Regulation of the transcriptional activity of
nuclear receptors by the MEK/ERK1/2 pathway. Cell Signal.
24:2369–2377. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gao N, Budhraja A, Cheng S, Liu EH, Huang
C, Chen J, Yang Z, Chen D, Zhang Z and Shi X: Interruption of the
MEK/ERK signaling cascade promotes dihydroartemisinin-induced
apop-tosis in vitro and in vivo. Apoptosis. 16:511–523. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lieske NV, Tonby K, Kvale D, Dyrhol-Riise
AM and Tasken K: Targeting tuberculosis and HIV infection-specific
regulatory T cells with MEK/ERK signaling pathway inhibitors. PLoS
One. 10:e01419032015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ren J, Zhang N, Liao H, Chen S, Xu L, Li
J, Yang Z, Deng W and Tang Q: Caffeic acid phenethyl ester
attenuates pathological cardiac hypertrophy by regulation of
MEK/ERK signaling pathway in vivo and vitro. Life Sci. 181:53–61.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen WF, Wu L, Du ZR, Chen L, Xu AL, Chen
XH, Teng JJ and Wong MS: Neuroprotective properties of icariin in
MPTP-induced mouse model of Parkinson's disease: Involvement of
PI3K/Akt and MEK/ERK signaling pathways. Phytomedicine. 25:93–99.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dobberkau HJ: Problems in the hygienic
evaluation of flowing waters. Z Gesamte Hyg. 21:738–741. 1975.In
German. PubMed/NCBI
|
|
31
|
Wu JH, Xu P, Yi MY, Wang F, Wang XL and
Huang Q: Analysis of angiogenesis associated factors of
retinoblastoma cell line and tumor tissues. Zhonghua Yan Ke Za Zhi.
41:419–422. 2005.In Chinese. PubMed/NCBI
|
|
32
|
Steelman LS, Abrams SL, Shelton JG,
Chappell WH, Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra M,
Martelli AM and McCubrey JA: Dominant roles of the Raf/MEK/ERK
pathway in cell cycle progression, prevention of apoptosis and
sensitivity to chemotherapeutic drugs. Cell Cycle. 9:1629–1638.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang L, Ji Q, Liu X, Chen X, Chen Z, Qiu
Y, Sun J, Cai J, Zhu H and Li Q: Norcantharidin inhibits tumor
angiogenesis via blocking VEGFR2/MEK/ERK signaling pathways. Cancer
Sci. 104:604–610. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hong SK, Yoon S, Moelling C, Arthan D and
Park JI: Noncatalytic function of ERK1/2 can promote
Raf/MEK/ERK-mediated growth arrest signaling. J Biol Chem.
284:33006–33018. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar
|
|
36
|
Liu H and Zhou M: Antitumor effect of
Quercetin on Y79 retinoblastoma cells via activation of JNK and p38
MAPK pathways. BMC Complement Altern Med. 17:5312017. View Article : Google Scholar : PubMed/NCBI
|
